Neurology, Neuropsychiatry, Psychosomatics

Advanced search


Full Text:


Multiple sclerosis (MS) is the most common and potentially disabling disease of the central nervous system in young people. Not only inflammatory, but also neurodegenerative processes are involved in the pathogenesis of MS. The use of MS-modifying drugs (MSMDs)  has led to a substantial reduction in the frequency of MS exacerbations and to the slower development of irreversible neurological deficit. Glatiramer acetate is one of the MSMDs of first choice and has a dual (anti-inflammatory and neuroprotective) action. The drug has proven to be effective and safe if administered long-term. Therapy with glatiramer acetate has been established to promote the production of anti-inflammatory cytokines and neurotrophic factors, which prevent the development of a degenerative process and stimulate remyelination, and to slow the progression of cerebral atrophy. Experimental findings suggest that the drug improves the processes of neurogenesis.

The efficiency of treatment is known to be associated with patient medication adherence. This largely depends on the frequency and route of drug administration and on the development of adverse events (AEs). To improve treatment adherence to glatiramer acetate, its new 40-mg formulation has been designed, which allows it to be administered only thrice weekly. The use of the formulation has demonstrated its efficacy and safety and resulted in a considerable reduction in the incidence rate of AEs.

About the Author

T. E. Shmidt
I.M. Sechenov First Moscow State Medical University
Russian Federation

Tatiana Evgenyevna Shmidt - Department of Nervous System Diseases and Neurosurgery.

11, Rossolimo St., Moscow 119021,


1. Шмидт ТЕ, Яхно НН. Рассеянный склероз. Москва: МЕДпресс-информ; 2010. 267 с. [Shmidt TE, Yakhno NN. Rasseyannyi skleroz [Multiple sclerosis]. Moscow: MEDpressinform; 2010. 267 p.]

2. Aharoni R, Vainstein A, Stock A, et al. Distinct pathological patterns in relapsingremitting and chronic models of EAE and neuroprotective effect of glatiramer acetate. J Autoimmun. 2011 Nov;37(3):228-41. doi: 10.1016/j.jaut.2011.06.003. Epub 2011 Jul 14.

3. Coustans M, Leray E, Le Page E, et al. Both relapsing-remitting and primary progressive MS are a two-stage disease, suggesting two consecutive mechanisms underlying progression of disability in MS. MS J. 2004;10 Suppl. 2:70.

4. Lassman H. Recent neuropathological findings in MS. J Neurol. 2004;251 Suppl. 4:2-5.

5. Гусев ЕИ, Завалишин ИА, Бойко АН, редакторы. Рассеянный склероз. Москва: Реал Тайм; 2011. 315 с. [Gusev EI, Zavalishin IA, Boiko AN, editors. Rasseyannyi skleroz [Multiple sclerosis]. Moscow: Real Taim; 2011. 315 p.]

6. Colman D, Lubetzki C, Reingold S. Multiple paths towards repair in multiple sclerosis. Trends Neurosci. 2003 Feb;26(2):59-61.

7. Arnon R, Aharoni R. Neuroprotection and neurodegeneration in MS and its animal model EAE effected by glatiramer acetate. J Neural Transm (Vienna). 2009 Nov;116(11):1443-9. doi: 10.1007/s00702-009-0272-3. Epub 2009 Aug 11.

8. Chen M, Valenzuela R, Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci. 2003 Nov 15;215(1-2):37-44.

9. Besser M, Wank R. Cutting edge clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol. 1999 Jun 1;162(11): 6303-6.

10. Khan O, Shen Y, Caon C, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsingremitting multiple sclerosis. Mult Scler. 2005 Dec;11(6):646-51.

11. Rieckman P, Maurer M. Axonal damage in MS: possible mechanisms. Curr Opin Neurol. 2002 Jun;15(3):361-70.

12. Khan O, Bao F, Shah M, et al Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study. J Neurol Sci. 2012 Jan 15;312(1-2):7-12. doi: 10.1016/j.jns.2011.08.034. Epub 2011 Sep 13.

13. Ford C, Johnson K, Brooks B, et al. Sustained efficacy and tolerability of glatiramer acetate in relapsing-remitting multiple sclerosis patients over 10 years. Proceeding of 19th Annual Meeting of the ECTRIMS; 2003. 485 p.

14. Елагина ИА, Шмидт ТЕ. Утомляемость при рассеянном склерозе. Неврологический журнал. 2008;(1):37-45. [Elagina IA, Shmidt TE. Fatigue in multiple sclerosis. Nevrologicheskii zhurnal. 2008;(1):37-45. (In Russ.)].

15. Шмидт ТЕ. Когнитивные нарушения и попытки их коррекции при рассеянном склерозе. Журнал неврологии и психиатрии им. С.С. Корсакова. 2005;(3):34-41. [Shmidt TE. Cognitive disorders and attempts of correction in multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2005;(3):34-41. (In Russ.)].

16. Khan O, Reickmann P, Boyko A, et al Three time weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013 Jun;73(6):705-13. doi: 10.1002/ana.23938. Epub 2013 Jun 28.

17. Wolinsky J, Borresen T, Dietrich D, et al. GLACIER: an open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-time weekly versus 20 mg daily in patients with relapsingremitting multiple sclerosis. Mult Scler Relat Disord. 2015 Jul;4(4):370-6. doi: 10.1016/j.msard.2015.06.005. Epub 2015 Jun 14.


For citations:


Views: 3266

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)